TITLE

Myelodysplastic syndromes and the role of iron overload

AUTHOR(S)
Harvey, R. Donald
PUB. DATE
April 2010
SOURCE
American Journal of Health-System Pharmacy;4/1/2010 Supplement, Vol. 67, pS3
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. The epidemiology of myelodysplastic syndromes (MDS) and iron overload, recent clinical findings that highlight the importance of actively managing iron overload, and recommendations for initiating and maintaining iron chelation therapy (ICT) are summarized. Summary. MDS are a variety of hematological disorders with differing time courses. Disease morbidities are primarily due to cytopenias and evolution to acute myeloid leukemia. Iron overload is a serious complication in patients with MDS due to the long-term use of red blood cell transfusions in patients with symptomatic anemia. Clinical consequences of iron overload include end-organ damage and dysfunction, an increased frequency of transplant-related complications, and reduced survival rates. To prevent these complications, recommendations for initiating and maintaining ICT should be followed by clinicians caring for patients with MDS and iron overload. Conclusion. As current therapeutic options for patients with MDS do not always reduce the transfusion burden, many patients will still need long-term transfusion therapy. Strategies for the management of iron overload in MDS should be considered early in the disease course and in appropriate patients in order to prevent negative clinical outcomes associated with excessive iron accumulation.
ACCESSION #
48911306

 

Related Articles

  • The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes. Petrou, Emmanouil; Mavrogeni, Sophie; Karali, Vasiliki; Kolovou, Genovefa; Kyrtsonis, Marie-Christine; Sfikakis, Petros P.; Panayiotidis, Panayiotis // Revista Brasileira de Hematologia e Hemoterapia;Jul/Aug2015, Vol. 37 Issue 4, p252 

    Myelodysplastic syndromes represent a group of heterogeneous hematopoietic neoplasms derived from an abnormal multipotent progenitor cell, characterized by a hyperproliferative bone marrow, dysplasia of the cellular hemopoietic elements and ineffective erythropoiesis. Anemia is a common finding...

  • Iron overload in myelodysplastic syndromes. Harvey, R. Donald; Fausel, Christopher A. // American Journal of Health-System Pharmacy;4/1/2010 Supplement, Vol. 67, pS2 

    The article focuses on iron overload, a clinical complication resulted from myelodysplastic syndromes (MDS). It discusses the importance of management strategies in patients with MDS to address the consequences of overload, and the use of iron chelation therapy (ICT) as a treatment for MDS. It...

  • Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. De Sanctis, Vincenzo; Soliman, Ashraf T.; Elsedfy, Heba; Skordis, Nicos; Kattamis, Christos; Angastiniotis, Michael; Karimi, Mehran; Yassin, Mohd Abdel Daem Mohd; El Awwa, Ahmed; Stoeva, Iva; Raiola, Giuseppe; Galati, Maria Concetta; Bedair, Elsaid M.; Fiscina, Bernadette; El Kholy, Mohamed // Indian Journal of Endocrinology & Metabolism;Jan/Feb2013, Vol. 17 Issue 1, p8 

    The current management of thalassemia includes regular transfusion programs and chelation therapy. It is important that physicians be aware that endocrine abnormalities frequently develop mainly in those patients with significant iron overload due to poor compliance to treatment, particularly...

  • Transfusion-dependent low-risk myelodysplastic patients receiving deferasirox: Long-term follow-up. IMPROTA, SALVATORE; VILLA, MARIA ROSARIA; VOLPE, ANTONIO; LOMBARDI, ANGELA; STIUSO, PAOLA; CANTORE, NICOLA; MASTRULLO, LUCIA // Oncology Letters;2013, Vol. 6 Issue 6, p1774 

    Myelodysplastic syndromes (MDSs) are characterized by ineffective hematopoiesis that results in peripheral cytopenias. Anemia is the most common symptom of MDS and the majority of patients become transfusion-dependent with the risk of iron overload, which may lead to cardiac, hepatic and...

  • Iron chelation therapy in myelodysplastic syndromes. Fausel, Christopher A. // American Journal of Health-System Pharmacy;4/1/2010 Supplement, Vol. 67, pS10 

    Purpose. To understand how to appropriately recognize and manage iron overload with iron chelation therapy (ICT) in patients with myelodysplastic syndromes (MDS), evaluation of the role of different agents available for management of iron overload, including efficacy, safety, and...

  • Iron Chelation Therapy in Myelodysplastic Syndromes. Messa, Emanuela; Cilloni, Daniela; Saglio, Giuseppe // Advances in Hematology;2010, Vol. 2010, p1 

    Myelodysplastic syndromes (MDS) are a heterogeneous disorder of the hematopoietic stem cells, frequently characterized by anemia and transfusion dependency. In low-risk patients, transfusion dependency can be long lasting, leading to iron overload. Iron chelation therapy may be a therapeutic...

  • Successful Chelation Therapy in a Case of Neonatal Iron Overload Following Intravascular Intrauterine Transfusion. Sreenan, Con; Idikio, Halliday A; Osiovich, Horacio // Journal of Perinatology;Dec2000, Vol. 20 Issue 8, p509 

    OBJECTIVE: We report a newborn infant who was successfully treated with chelation therapy having developed severe liver disease secondary to iron overload following multiple intrauterine, intravascular transfusions (IVTs). STUDY DESIGN: Case report with review of the literature. RESULTS: An...

  • Μέθοδοι αποσιδήρωσηϛ: μια βιβλιογραφική... Maria, Agapiou; Elpida, Georgiadi // Rostrum of Asclepius / Vima tou Asklipiou;jan-mar2012, Vol. 11 Issue 1, p5 

    "Iron Chelation Therapy" is a term used to describe the procedure of removing excess iron from the body, which is applied after a total of approximately 20 blood transfusions or when serum ferritin levels rise above 1000 ng/ml. Aim: The purpose of the present paper is a retrospective search in...

  • Comparison of Blood Transfusion Plus Chelation Therapy and Bone Marrow Transplantation in Patients with ß-Thalassemia: Application of SF-36, EQ-5D, and Visual Analogue Scale Measures. Javanbakht, Mehdi; Keshtkaran, Ali; Shabaninejad, Hossien; Karami, Hassan; Zakerinia, Maryam; Delavari, Sajad // International Journal of Health Policy & Management;Nov2015, Vol. 4 Issue 11, p733 

    Background: β-Thalassemia is a prevalent genetic disease in Mediterranean countries. The most common treatments for this disease are blood transfusion plus iron chelation (BTIC) therapy and bone marrow transplantation (BMT). Patients using these procedures experience different health-related...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics